Patents by Inventor Yonghong Liang

Yonghong Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240307829
    Abstract: The present disclosure relates to a composite reverse osmosis membrane and a preparation method therefor. The preparation method of the present disclosure can realize the preparation of a composite reverse osmosis membrane having a high flux, a high desalinization rate, a high deboration rate and high contamination resistance in a simple operation and high reaction efficiency manner.
    Type: Application
    Filed: December 6, 2021
    Publication date: September 19, 2024
    Inventors: Songmiao Liang, Lijie Hu, Lianrui Zhao, Xingsheng Yang, Yonghong Liang, Jun Fang, Yan Jin, Zongce Wu
  • Publication number: 20240270759
    Abstract: The present invention has disclosed SHP2 phosphatase inhibitors and its applications. Specifically, the present invention has disclosed the compounds shown in the general formula (I), methods of preparation thereof, and pharmaceutical compositions containing the compound, and their use as tyrosine phosphatase SHP-2 inhibitors in the treatment of leukemia, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, pancreatic cancer, head and neck squamous cell carcinoma, stomach cancer, liver cancer, anaplastic large cell lymphoma, and glioblastoma, wherein each substituent in general formula (I)k is as defined in the specification.
    Type: Application
    Filed: May 7, 2022
    Publication date: August 15, 2024
    Inventors: Yonghong LIANG, Zhiyong XU, Zhaosen ZENG, Wenguang YAN, Fangjun XIONG
  • Publication number: 20240190871
    Abstract: KRASG12D mutant protein inhibitors, as shown by formula (I), a composition containing the inhibitor and pharmaceutically acceptable salt, syntheses, intermediates, formulations, and the use thereof. The compounds of the invention have good activity and safety in inhibiting tumor growth.
    Type: Application
    Filed: February 9, 2022
    Publication date: June 13, 2024
    Inventors: Yonghong LIANG, Zhiyong XU
  • Publication number: 20240190864
    Abstract: Disclosed are a heterocyclic compound acting as a BTK (Bruton's Tyrosine Kinase) inhibitor, a preparation method and a medical application thereof. Specifically, the present disclosure relates to a compound represented by the general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound and/or the pharmaceutically acceptable salt thereof, and a use applying the compound or the pharmaceutically acceptable salt in the treatment or prevention of BTK-related disorders, especially tumors. The present disclosure relates to a class of heterocyclic compounds and at the same time provides the preparation method for the pharmaceutical composition containing this class of compounds or the pharmaceutically acceptable salt thereof. Each substituent of the general formula (I) has the same definition as that in the specification.
    Type: Application
    Filed: December 27, 2021
    Publication date: June 13, 2024
    Inventors: Yonghong LIANG, Zhiyong XU, Zhaosen ZENG, Wenguang YAN, Fangjun XIONG
  • Publication number: 20240182470
    Abstract: A KRASG12C mutant protein inhibitor, as shown by formula (I), a composition containing the inhibitor and pharmaceutically acceptable salt, syntheses, intermediates, formulations, and the use thereof. The compounds of the invention have good activity and safety in inhibiting tumor growth.
    Type: Application
    Filed: March 7, 2022
    Publication date: June 6, 2024
    Inventors: Yonghong LIANG, Zhiyong XU
  • Publication number: 20240109896
    Abstract: Disclosed are a heterocyclic compound used as a FGFR (Fibroblast Growth Factor Receptor) inhibitor, a preparation method thereof, and a pharmaceutical application thereof. Specifically, the present disclosure relates to a compound represented by general formula I and a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the found and/or the pharmaceutically acceptable salt, and a use of the compound or the pharmaceutically acceptable salt in treating or preventing disorders related to FGFR kinase, specifically tumor drugs, and the compound is a class of heterocyclic compound, and at the same time the present disclosure provides a preparation method for the pharmaceutical composition of the compound and the pharmaceutically acceptable salt. Definition of substituents in general formula I is identified with that in the description.
    Type: Application
    Filed: December 27, 2021
    Publication date: April 4, 2024
    Inventors: Yonghong LIANG, Zhiyong XU, Zhaosen ZENG, Wenguang YAN, Fangjun XIONG
  • Patent number: 8809343
    Abstract: A pyrimidine derivative and the preparation method and use thereof. The said pyrimidine derivative is a diaryl pyrimidine derivative or a diaryl benzo pyrimidine derivative which has the structure shown as the Formula I and IV. Present pyrimidine derivative can be used for the prevention or the treatment of HIV.
    Type: Grant
    Filed: December 24, 2009
    Date of Patent: August 19, 2014
    Assignee: Fudan University
    Inventors: Fener Chen, Yonghong Liang, Zhaosen Zeng
  • Publication number: 20120122902
    Abstract: A pyrimidine derivative and the preparation method and usethereof. The said pyrimidine derivative is a diaryl pyrimidine derivative or a diaryl benzo pyrimidine derivative which has the structure shown as the Formula I and IV. Present pyrimidine derivative can be used for the prevention or the treatment of HIV.
    Type: Application
    Filed: December 24, 2009
    Publication date: May 17, 2012
    Applicant: FUDAN UNIVERSITY
    Inventors: Fener Chen, Yonghong Liang, Zhaosen Zeng